Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Illumina (ILMN – Research Report). The associated price target remains the same with $105.00. Michael Ryskin’s ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) yesterday and set a price target of $242.00. The company’s shares closed last Friday at $104.38.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. Not all ...

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...

Illumina operates in the genetic and genomic analysis sector, providing products and services for research and clinical environments. The company's strategic priorities include achieving top-line ...